Company News 

Clinigen feels the benefit of a diversified business

Clinigen feels the benefit of a diversified business

It is rare to see any sign of weakness from specialist pharma group Clinigen (CLIN), so investors were spooked by news that adjusted gross profits in the clinical trials division fell 34 per cent in the first half of the 2018 financial year. Fortunately, chief executive Shaun Chilton has dealt with the issue. By “changing the leadership of that business”, he is confident that it will perform much better in the second half. Clinical trials services – which currently only contributes 10 per cent of gross profits – has exciting potential due to a rise in outsourcing from big pharma companies.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now